Cargando…

Sleep Disturbance, Irritability, and Response to Lurasidone Treatment in Children and Adolescents with Bipolar Depression

BACKGROUND: The presence of mixed (subsyndromal hypomanic) symptoms may influence treatment outcomes in pediatric bipolar depression. This post-hoc analysis investigated “bridge” symptoms that have cross-sectional and predictive associations with depressive and manic symptom clusters in youth with b...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Manpreet K., Siu, Cynthia, Tocco, Michael, Pikalov, Andrei, Loebel, Antony
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2023
Materias:	Medicine, Neurology, Pharmacology, Neuroscience
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10324333/ https://www.ncbi.nlm.nih.gov/pubmed/36173066 http://dx.doi.org/10.2174/1570159X20666220927112625

Ejemplares similares

Lurasidone in Children and Adolescents with Bipolar Depression Presenting with Mixed (Subsyndromal Hypomanic) Features: Post Hoc Analysis of a Randomized Placebo-Controlled Trial
por: Singh, Manpreet K., et al.
Publicado: (2020)

PS37. Lurasidone in the Treatment of Bipolar Depression: Effect of Baseline Depression Severity on Clinical Outcome
por: Pikalov, Andrei, et al.
Publicado: (2016)

F60. INFLAMMATORY MARKERS AND COGNITIVE PERFORMANCE IN PATIENTS WITH SCHIZOPHRENIA TREATED WITH LURASIDONE
por: Pikalov, Andrei, et al.
Publicado: (2018)

Tolerability, Safety, and Effectiveness of Two Years of Treatment with Lurasidone in Children and Adolescents with Bipolar Depression
por: DelBello, Melissa P., et al.
Publicado: (2021)

Effects on health-related quality of life in patients treated with lurasidone for bipolar depression: results from two placebo controlled bipolar depression trials
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

F52. EFFICACY AND SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
por: Goldman, Robert, et al.
Publicado: (2018)

T5. LURASIDONE AND RISK FOR METABOLIC SYNDROME IN PATIENTS WITH SCHIZOPHRENIA: A COMPREHENSIVE DATABASE ANALYSIS
por: Tocco, Michael, et al.
Publicado: (2018)

The direct and indirect effects of lurasidone monotherapy on functional improvement among patients with bipolar depression: results from a randomized placebo-controlled trial
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Long-term use of lurasidone in patients with bipolar disorder: safety and effectiveness over 2 years of treatment
por: Pikalov, Andrei, et al.
Publicado: (2017)

PM413. Metabolic Syndrome in Patients With Schizophrenia Receiving Long-Term Treatment With Lurasidone, Quetiapine XR, or Risperidone
por: Newcomer, John W., et al.
Publicado: (2016)

Lurasidone: a novel antipsychotic agent for the treatment of schizophrenia and bipolar depression
por: Loebel, Antony, et al.
Publicado: (2015)

Switching to Lurasidone following 12 months of treatment with Risperidone: results of a 6-month, open-label study
por: Mattingly, Greg W., et al.
Publicado: (2020)

Daytime sleepiness associated with lurasidone and quetiapine XR: results from a randomized double-blind, placebo-controlled trial in patients with schizophrenia
por: Loebel, Antony D., et al.
Publicado: (2013)

Lurasidone for the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies
por: Nasrallah, Henry A., et al.
Publicado: (2014)

Lurasidone for the Treatment of Irritability Associated with Autistic Disorder
por: Loebel, Antony, et al.
Publicado: (2015)

Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia
por: Meyer, Jonathan M., et al.
Publicado: (2015)

Lurasidone in adolescents with schizophrenia: Sustained remission and recovery during 2 years of open-label treatment
por: Tocco, M., et al.
Publicado: (2021)

Health-related quality of life among patients treated with lurasidone: results from a switch trial in patients with schizophrenia
por: Awad, George, et al.
Publicado: (2014)

A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
por: Tandon, Rajiv, et al.
Publicado: (2016)

Short-term efficacy and safety of lurasidone versus placebo in antipsychotic-naïve versus previously treated adolescents with an acute exacerbation of schizophrenia
por: Correll, Christoph U., et al.
Publicado: (2022)

S73. EFFECT OF LURASIDONE ON COGNITION IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 2-YEAR OPEN-LABEL EXTENSION STUDY
por: Harvey, Philip D, et al.
Publicado: (2018)

Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia
por: Awad, George, et al.
Publicado: (2016)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies
por: Costamagna, Isabella, et al.
Publicado: (2021)

Change in daytime sleepiness and cognitive function in a 6-month, double-blind study of lurasidone and quetiapine XR in patients with schizophrenia
por: Harvey, Philip D., et al.
Publicado: (2016)

Efficacy and safety of lurasidone in adolescents and young adults with schizophrenia: Pooled analysis of double-blind, placebo-controlled 6-week studies
por: Calisti, F., et al.
Publicado: (2021)

PM418. Efficacy of Lurasidone in Patients With Schizophrenia With Prominent Positive Symptoms: A Pooled Analysis of Short-Term Placebo-Controlled Studies
por: Potkin, Steven G., et al.
Publicado: (2016)

LURASIDONE IN THE LONG‐TERM TREATMENT OF PATIENTS WITH BIPOLAR DISORDER: A 24‐WEEK OPEN‐LABEL EXTENSION STUDY
por: Ketter, Terence A., et al.
Publicado: (2016)

Lurasidone for the treatment of bipolar depression: an evidence-based review
por: Franklin, Rachel, et al.
Publicado: (2015)

Management of bipolar I depression: clinical utility of lurasidone
por: Findlay, Lillian Jan, et al.
Publicado: (2015)

Antipsychotic treatments; focus on lurasidone
por: Sumiyoshi, Tomiki
Publicado: (2013)

Efficacy and Safety of Lurasidone in Adolescents with Schizophrenia: A 6-Week, Randomized Placebo-Controlled Study
por: Goldman, Robert, et al.
Publicado: (2017)

S5. DOES THE TIME OF DRUG ADMINISTRATION ALTER THE ADVERSE EVENT RISK OF LURASIDONE?
por: Hagi, Katsuhiko, et al.
Publicado: (2020)

Lurasidone in the Treatment of Bipolar Depression: Systematic Review of Systematic Reviews
por: Fornaro, Michele, et al.
Publicado: (2017)

Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
por: Rajagopalan, Krithika, et al.
Publicado: (2016)

Lurasidone for Treating Schizophrenia and Bipolar Depression: A Review of Its Efficacy
por: Tarzian, Martin, et al.
Publicado: (2023)

Lurasidone compared to other atypical antipsychotic monotherapies for adolescent schizophrenia: a systematic literature review and network meta-analysis
por: Arango, Celso, et al.
Publicado: (2019)

Lurasidone as a potential therapy for bipolar disorder
por: Woo, Young Sup, et al.
Publicado: (2013)

Association Between Irritable Bowel Syndrome and Sleep Disturbance in Adolescents
por: Indah Kusumawati Noor, Laili, et al.
Publicado: (2020)

Early Family Intervention for Youth at Risk for Bipolar Disorder: Psychosocial and Neural Mediators of Outcome
por: Miklowitz, David J., et al.
Publicado: (2023)

Hospitalization outcomes in patients with schizophrenia after switching to lurasidone or quetiapine: a US claims database analysis
por: Newcomer, John W., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_of3harcuh8ro6ur7s47tuqqf6v